Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2007-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1365-2125.2007.02934.XPMID 17555465PMCID PMC2198786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation

  2006cited by this paper
• The natural history of chronic allograft nephropathy.

  2005cited by this paper
• Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment

  2005cited by this paper
• Influence of Co‐Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation

  2005cited by this paper
• Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.

  2004cited by this paper
• Cyclosporin A, but Not Tacrolimus, Inhibits the Biliary Excretion of Mycophenolic Acid Glucuronide Possibly Mediated by Multidrug Resistance-Associated Protein 2 in Rats

  2004cited by this paper
• WOUND-HEALING COMPLICATIONS AFTER KIDNEY TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED COMPARISON OF SIROLIMUS AND TACROLIMUS1

  2004cited by this paper
• Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era

  2004cited by this paper
• The natural history of chronic allograft nephropathy.

  2003cited by this paper
• Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients

  2003cited by this paper
• Comparison of Sirolimus vs. Mycophenolate Mofetil on Surgical Complications and Wound Healing in Adult Kidney Transplantation

  2003cited by this paper
• Immunosuppression: practice and trends

  2003cited by this paper
• Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine1

  2002cited by this paper
• Mycophenolic Acid Plasma Concentrations: Influence of Comedication

  2001cited by this paper
• A WORLDWIDE, PHASE III, RANDOMIZED, CONTROLLED, SAFETY AND EFFICACY STUDY OF A SIROLIMUS/CYCLOSPORINE REGIMEN FOR PREVENTION OF ACUTE REJECTION IN RECIPIENTS OF PRIMARY MISMATCHED RENAL ALLOGRAFTS

  2001cited by this paper
• Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin).

  2001cited by this paper
• Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

  2001cited by this paper
• Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

  2000cited by this paper
• Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future.

  2000cited by this paper
• Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.

  2000cited by this paper
• Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management.

  2000cited by this paper
• Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.

  2000cited by this paper
• Role of multidrug‐resistance protein 2 in glutathione S‐transferase P1‐1–mediated resistance to 4‐nitroquinoline 1‐oxide toxicities in HepG2 cells

  2000cited by this paper
• Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

  2000cited by this paper
• Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study.

  1999cited by this paper
• Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients.

  1999cited by this paper
• Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.

  1999cited by this paper
• Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

  1999cited by this paper
• The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent

  1998cited by this paper
• Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression.

  1998cited by this paper
• Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin).

  1998cited by this paper
• Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group

  1997cited by this paper
• Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group.

  1997cited by this paper
• The effect of race and ethnicity on kidney allograft outcome.

  1995cited by this paper
• The adverse impact of cyclosporine on serum lipids in renal transplant recipients.

  1991cited by this paper
• Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients

  1991cited by this paper
• Impact of race on the outcome of renal transplantation under cyclosporine-prednisone.

  1989cited by this paper
• Kidney graft survival rates in black cyclosporine-treated recipients. Collaborative Transplant Study.

  1989cited by this paper
• Human gene mapping 3. Baltimore Conference (1975). Third International Workshop on Human Gene Mapping. Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6.

  1976cited by this paper
• Measurement of glomerular filtration rate by fluorescent excitation of non-radioactive meglumine iothalamate.

  1975cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• A Mycophenolate Pharmacokinetic Study with New Insights into Enterohepatic Recirculation in Kidney Transplant Recipients.

  2026cites this paper
• Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis.

  2024cites this paper
• Limited Sampling Strategies Fail to Accurately Predict Mycophenolic Acid Area Under the Curve in Kidney Transplant Recipients and the Impact of Enterohepatic Recirculation

  2024cites this paper
• Diabetes is a significant and independent predictor for tacrolimus immediate release and LCP‐tacrolimus conversion ratios

  2023cites this paper
• Tremor Induced by Cyclosporine, Tacrolimus, Sirolimus, or Everolimus: A Review of the Literature

  2023cites this paper
• Mammalian Target of Rapamycin Inhibitors and Wound Healing Complications in Kidney Transplantation: Old Myths and New Realities

  2022cites this paper
• A short overview on mycophenolic acid pharmacology and pharmacokinetics.

  2020cites this paper
• Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

  2019cites this paper
• Maintenance Immunosuppression in Kidney Transplantation

  2017cites this paper
• Therapeutic Drug Monitoring of Mycophenolic Acid.

  2016cites this paper
• Immunological risks of minimization strategies

  2015cites this paper
• Calcineurin inhibitor sparing strategies in renal transplantation, part one: Late sparing strategies.

  2014cites this paper
• Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data

  2014cites this paper
• Effect of Cyclosporine on Steady-State Pharmacokinetics of MPA in Renal Transplant Recipients Is Not Affected by the MPA Formulation: Analysis Based on Therapeutic Drug Monitoring Data

  2014cites this paper
• The metabolic and toxicological considerations for immunosuppressive drugs used during pancreas transplantation

  2012cites this paper
• Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation: A Critical Review of the Literature

  2012influential citation
• Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

  2011cites this paper
• Immunosuppression: does one regimen fit all?

  2011cites this paper
• Interleukin 2 receptor antagonists for kidney transplant recipients.

  2010cites this paper
• Sirolimus for calcineurin inhibitors in organ transplantation: contra.

  2010cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Immunotherapy in Elderly Transplant Recipients Guide to Clinically Significant Drug Interactions

  2009cites this paper
• The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.

  2009cites this paper
• Immunotherapy in Elderly Transplant Recipients

  2009cites this paper
• Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics

  2009cites this paper
• Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring.

  2008cites this paper
• Development of a Predictive Limited Sampling Strategy for Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Patients Receiving Concomitant Sirolimus or Cyclosporine

  2008cites this paper
• Drugs and the kidney: more than a question of dose.

  2007cites this paper
• Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

  2006cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  1996cites this paper